Investors

Human Utility Value

“We are building a community of shareholder partners with a vision to optimize Human Utility Value while maximizing shareholder return. BioHarvest Sciences offers investors a rare opportunity to participate in a disruptive technology that promises both sustainable corporate growth AND improves human Health & Wellness.”

— Ilan Sobel, CEO

***BioHarvest Sciences to begin Trading on Nasdaq November 12, 2024 ***

CEO Ilan Sobel and Chairman Dr. Zaki Rakib were interviewed November 7, 2024, to discuss the announcement that BioHarvest shares will begin trading on Nasdaq under the symbol “BHST” on Tuesday November 12. The company will continue to be listed on the Canadian Securities Exchange as “BHSC”.

Watch Interview

BioHarvest Sciences is a global leader in Botanical Synthesis and Plant Cell Biology

  • Innovative and disruptive Botanical Synthesis Platform opening the gate for patentable Botanical Drugs
    • New Contract Development and Manufacturing business unit launched February 26, 2024 with two industry contracts.  Pharma, Cosmeceutical, Nutraceutical and Nutrition customers can now develop patentable and consistent  plant-based molecules using our process.
  • Our patented Botanical Synthesis technology has been validated by the successful commercialization of VINIA, the first product developed on our platform.
    • Full Year 2023 Revenue Increased 2.3x to $12.7 Million USD
    • Q2 2024 Revenue beat guidance at $6.03 million and Q3 2024 Preliminary Revenue is $6.5 million
    • Second quarter 2024 gross margins were 52%, as compared to 40% in the second quarter of 2023
  • New “VINIA Inside” delivery systems are in the product  pipeline, including additional Hot Beverage products,  hydration powders, and new Beauty/Anti Aging products
  • Major innovation pipeline planned in the polyphenol/antioxidant vertical with additional products being developed from Olive and Pomegranate cell banks
  • Strong IP platform with multiple patents obtained and pending
  • High Scalability with low cap ex requirements ($3-4M)
  • Significant leadership capability and Board/Advisory Board expertise
  • Current market capitalization offers significant upside
Vinia
corporate presentation

Request a Meeting

Our news

The world leading plant-cell growth company

BioHarvest has transformed from a Research and Development company into a full-fledged end-to-end operation, with over 100% revenue growth year over year on our Polyphenol Antioxidant Product business, new products and new market entries targeted for 2024, and the February 2024 launch of the CDMO Services business unit.

November 7, 2024

BioHarvest Sciences to Begin Trading on Nasdaq on November 12, 2024

CEO Ilan Sobel and Chairman Dr. Zaki Rakib discuss the announcement that BioHarvest will trade on Nasdaq under the symbol BHST

August 29, 2024

BioHarvest Reports Q2 Revenues Exceed $6Million and Releases new Product Pipeline

CEO Ilan Sobel shares the company’s financial and operational results, with Q2 2024 revenues of $6.03 Million.

April 01 2023

Jerusalem Dateline interview

The BioHarvest Team explains the power of this unique biotechnology platform, as we grow plant cells without the plant.

0

Patents

0

Clinical Studies

0

Scientific Studies

0

Years R&D

$ 0

Million Invested

News Feed

Join the BioHarvest community via any of our shared content channels. Share our daily progress and our major news:

Facebook Youtube Email alternate_emailCreated with Sketch.

Our blog